CureVac’s Fate Hangs in the Balance as Shareholders Vote on BioNTech Takeover

The independent existence of CureVac could soon be a chapter in corporate history. On November 25, shareholders will convene in Amsterdam for an extraordinary general meeting, facing a definitive vote on the German biotech firm’s future. The central item on the agenda is a proposed acquisition by rival BioNTech, valued at approximately $1.25 billion. The prevailing sentiment among market observers is not if the Tübingen-based company will be absorbed by its mRNA competitor, but when the transaction will be finalized.

This pivotal moment follows the commencement of BioNTech’s public share exchange offer on October 22. The bid, which targets all outstanding CureVac shares, is structured on Read more...